Tagged with innovation

Switzerland Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer modelling; and how it is looking to leverage its connections to the rest of Switzerland and to Italy.   A…

China Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why a more streamlined and data driven review process is positive news for the innovative pharmaceutical industry. However, Bouteiller cautions that…

Europe On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of ensuring that “patients have access to innovative and affordable medicines” and “to support the competitiveness, innovative capacity and sustainability of the EU’s pharmaceutical industry”.   This Pharmaceutical Strategy for Europe is seen…

USA In a recent article for PharmaBoardroom, Objective Capital’s David Crean took a look at the state of US innovation today and its long term sustainability. See below for data on the share of US executives who see innovation as a top priority post-COVID, Global Public Equity Issuance for the Biopharmaceutical…

Switzerland Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves Switzerland’s vast array of SMEs, and why the country needs to guard against complacency to stay ahead of the competition on innovation.   A successful culture needs to guard against complacency.…

USA David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability.   The life sciences industry within the United States makes significant contributions to both America’s health and economy and is a leader in R&D and innovation based on numerous proxies including patents received,…

Switzerland Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination.   Attractive conditions must be maintained both for the large pharmaceutical companies – which are well established in Switzerland, but for which the…

Global Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change management that the COVID-19 pandemic has thrown up, why company-HCP interaction might never be the same again, and shares some pearls of wisdom for other women in pharma.   I see Merck’s…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…

Norway Erik W. Jakobsen of Norwegian consultancy Menon Economics gives an overview of the key dynamics at play in Norway’s economy today and the growing role that healthcare and the life sciences plays within it. Jakobsen touches on why Norway needs to become more competitive as a life sciences investment destination,…

Switzerland Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients, as well as his perspectives on talent development within the industry.   Switzerland is very open to innovative products, and…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…